How it works

1. Build a cohort of patients on the drug you are studying from prescription records, with the index date at the prescription.

2. Add genotypes and turn them into diplotypes and metabolizer phenotypes, such as CYP2C19 metabolizer status. Add clinical scores such as ABCD-GENE.

3. Compare outcomes by metabolizer status with survival analysis, regression or machine learning.

Where Cipherome started

Cipherome was founded in 2015 to work on drug safety and efficacy with genomics. COMPASS grew out of that research.

Published work

ABCD-GENE Score and Bleeding in Post-PCI Patients: Implications for Guided De-Escalation of Antiplatelet Therapy
Coons JC, Polkowski K, Prebehalla L, Smith AC, Empey PE (University of Pittsburgh / UPMC). J Cardiovasc Pharmacol Ther 31, Jun 2026.
All data pre-processing and statistical analyses were run on the COMPASS platform.

Pharmacogenomic Testing for CYP2C19 Variants among Stroke Patients Treated with Clopidogrel: Opportunity for the Clinical Laboratory?
Wu AHB, Orahoske CM, Chen G, Estabil J, Yeo KJ. J Appl Lab Med 10(4), Apr 2025.
Co-authored by Jose Estabil of Cipherome.